

T: 0131-244 2528

E: irene.fazakerley@scotland.gsi.gov.uk



IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Chief Pharmacists NHS Boards
3. Hospital Pharmacy Managers
4. Medical Directors NHS Boards
5. Chief Executives NHS Boards

29 October 2013

Dear Healthcare Professional,

DRUG ALERT CLASS 2 no.26 2013 – action within 48 hours

Please see the attached drug alert for onward transmission as below.
Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Chief Pharmacists to forward on to Medicines Information Pharmacists

1. Please could Medical Directors forward this alert to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY

Finance, e-Health and Pharmaceuticals Directorate

DRUG ALERT

CLASS 2 MEDICINES RECALL

Action Within 48 Hours
Pharmacy, Clinic and Wholesaler Level Recall

Date: 29 October 2013

EL (13)/A/26

Our Ref: MDR 77-10/13

Dear Healthcare Professional,

Glaxo Wellcome UK Limited Trading as GlaxoSmithKline UK

**Imigran Injection/Subject
(Sumatriptan Succinate)**

PL 10949/0113

Description	Batch Number	Expiry Date	Pack Size	First Distributed
Imigran Inj/Subject Treatment	C640404	15/05/15	2x0.5ml	19 Sept 13
Imigran Inj/Subject Refill	C639899	04/06/15	2x0.5ml	02 Sept 13
Imigran Inj/Subject Treatment	C638748	04/06/15	2x0.5ml	23 Aug 13
Imigran Inj/Subject Refill	C638737	04/06/15	2x0.5ml	09 Sept 13
Imigran Inj/Subject Treatment	C636954	04/06/15	2x0.5ml	14 Aug 13

Glaxo Wellcome UK Limited Trading as GlaxoSmithKline UK are recalling the above batches of Imigran Injection/Subject to pharmacy, clinic and wholesaler level as a small number of syringes may have needles protruding from the needle shield.

The risk to the patient of finding an affected syringe is extremely low; the implication of patient exposure to a syringe with a protruding needle is the potential risk of infection.

Remaining stocks of the affected batch should be quarantined and returned to the original supplier for credit. For enquiries relating to stock returns please contact your original supplier.

For medical information enquiries please contact GSK on 0800 221441 or email customercontactuk@gsk.com

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Local area teams are asked to forward this to relevant clinics, general practitioners and community pharmacists for information.

Yours faithfully

Adam Burgess

Defective Medicines Report Centre
151 Buckingham Palace Road
London
SW1W 9SZ
Telephone +44 (0)20 3080 6574